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ABSTRACT 
Thyroid hormones are iodinated compounds that are critical to differentiation, 
apoptosis, and cellular processes in virtually every vertebrate cell. The thyroid gland 
produces mostly thyroxine (T4) and also 3 ', 3, 5-triiodothyronine (T3). T4 acts as a 
"prehormone" and is converted in the periphery into the more physiologically active T3 
via deiodination. Deiodination is also the process by which thyroid hormones are 
inactivated and thyroid hormone balance is maintained. Types 1 (Dl) and 2 (D2) 
deiodinase activate T4 into T3. Conversely, inactivation is accomplished by type 3 
iodothyronine deiodinase (03), which is the primary inactivator of both T4 and T3. 03 is 
highly expressed in fetal tissues and is re-expressed in adult tissues during 
pathophysiological states. This reactivated 03 leads to local inactivation of thyroid 
hormones, which is maladaptive in certain situations but may be adaptive in others. 
We hypothesize that 03 deficiency in hematopoietic cells will affect blood cell 
function and/or production during inflammatory stress, infection, and anemia. 
Methods: Human blood cell lines were stimulated with a tumor promoter and ionophore 
and assayed for deiodinase activity. Conditional knockout mice with blood-cell-specific 
03 def1ciency were generated. Their complete blood counts and thyroid function tests 
iv 
were studied to determine the correlation between D3 and the hematopoietic system in 
both the well state and eventually stress states. 
Results: Dl, D2 and D3 were not stimulated by stressors in vitro. D3 was successfully 
knocked out of the hematopoietic system in mice. Blood-cell-specific D3 deficient mice 
had blood cell counts that were not significantly different from that of mice with a 
functional enzyme in the normal state (baseline). Mice of both genotypes were euthyroid 
in the normal state. 
Conclusion: 03 deficiency in the hematopoietic system was not sufficient to induce 
pancytopenia or thyroid hormone derangement in the normal state. Future studies will 
investigate the possible role of D 1 and/or 02 in compensating for D3 deficiency. The 
development of a conditional 03 knockout in blood will provide a useful tool for 
studying the effect of D3 on blood function and/or development in inflammation, 
infection, and anemia in future studies. 
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INTRODUCTION 
Role of Thyroid Hormone 
Thyroid hormones (THs) are powerful regulators of physiologic processes in 
nearly every organ system. Animal and human studies of thyroid disease indicate that 
they are regulators of cellular metabolism and differentiation and that optimal thyroid 
status is necessary for normal growth, development, tissue differentiation, and metabolic 
balance. In childhood, lack ofTHs can cause cretinism and delayed growth. In adults, the 
effects ofTHs are evidenced in alterations in oxygen consumption and protein, 
carbohydrate, lipid, and vitamin metabolism. 
THs act by entering target cells via plasma membrane transporters and exert 
their physiological effects by binding to nuclear TH receptors (TRs), which act as a 
heterodimer with retinoid X receptors (RXRs), and in tum bind to TH response elements 
(TREs) to either enhance or repress transcription of specific target genes (Figure 1 ). 
Certain tissues, such as liver, have large amounts of nuclear TRs and respond to thyroid 
hormones with large changes in protein synthesis. Signaling through this pathway is 
affected by fluctuations in serum levels ofTHs, which alter physiological processes that 
can be observed in symptoms of patients with Graves' disease and Hashimoto's 
thyroiditis. 
T4 T4 t 
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Figure 1: Mechanism of TH action via its nuclear receptor. TH is transported 
across the plasma membrane and binds to its nuclear receptor (TR) which functions as a 
heterodimer with retinoid X receptor (RXR). Subsequent binding to a thyroid hormone 
response element (TRE) increases or decreases rates ofTH-regulated gene expression. 
Figure taken from the Boston University School of Medicine Endocrinology Syllabus, 
2011. 
Thyroid Hormone and Deiodinases 
The chemical structure of thyroid hormone is based on thyronine, which consists 
of two coupled tyrosine amino acid side chains. Each tyrosine ring has the ability to carry 
1-2 iodine atoms in an ortho configuration on either side of the oxygen atom, with a fully 
iodinated thyronine, i.e. 3 ' 5' ,3,5-tetraiodothyronine or thyroxine (T4), being the major 
secretory product of the thyroid gland. The thyroid gland also produces 3' ,3 ,5-
triiodothyronine (T3), which has one less iodine on its outer ring and is the most 
physiologically active form as it is the predominant TH that is bound to nuclear receptors. 
However, 80% of circulating T3 comes from peripheral conversion ofT4, which acts as a 
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prehormone or precursor to T3. The physiologically inactive form is 3 ',5' ,3-
triiodothyronine (rT3 or reverse T3), which contains one less iodine than T4 on the inner 
ring. Both T3 and rT3 can be further deiodinated into 3 ',3-diiodothyronine (T2), which is 
also physiologically inactive. 
The thyroid hormones T3, rT3 , and T2 are all converted from their precursors by 
selenocysteine-containing proteins called the iodothyronine deiodinases. The three 
identified deiodinases are type I iodothyronine deiodinase (D 1 ), type 2 iodothyronine 
deiodinase (D2), and type 3 iodothyronine deiodinase (D3). Each deiodinase is found in 
various tissues such as liver, brain, muscle, and placenta (Thyroid Disease Manager, 
www.thyroidmanager.org). Dl and D2 are known as activating enzymes while D3 is a 
deactivating enzyme. The activating enzymes are responsible for peripheral conversion of 
T4 into the more physiologically potent T3 through outer ring deiodination, while D3 is 
responsible for inactivation ofT4 into rT3 and T3 into T2 through inner ring 
deiodination. The substrates of each enzyme along with the products of enzyme 
metabolism are shown in Figure 2. 
3 
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Figure 2: Structural formulas of THs and their main deiodination pathways. 
The substrates and products of each deiodinase are shown here. D 1 acts primarily on T4 
and rT3 ; 02 acts primarily on T4; D3 acts on T4 and T3 . Figure adapted from Nakao 
2008. 
4 
D3 Structure and Regulation 
Type 3 iodothyronine deiodinase (D3) is the main physiological inactivator of 
THs. It converts T4 and T3 into their inactive derivatives rT3 and T2, respectively, 
through inner-ring deiodination. The enzyme is thought to control TH homeostasis by 
protecting tissues from an excess ofTH and has been found in a various tissues such as 
brain, liver, skin, intestine and placenta (Thyroid Disease Manager). D3 is abundantly 
present in fetal tissues such as liver, brain, different internal epithelia, umbilical arteries 
and vein, lung, heart, intestine and skin (Huang eta!. 1986, Vander Getrer eta/. 1997, 
Bates et a/. 1999). It has also been found in high levels in hepatocarcinomas, 
hemangiomas, and basal cell carcinomas (Thyroid Disease Manager). Because of its 
expression in fetal tissues and disease states, D3 has been named an "oncofetal protein." 
D3 appears to be an integral membrane protein that functions as a homodimer 
(Sagar et a!. 2008). In vitro studies of D3-containing microsomes show a Km for T3 of 6 
nM and a Km for T4 of37 nM (Dentice 2011). It has a half-life of about 12 hours and 
there is no evidence of it being regulated at the post-transcriptionallevel (Gereben eta/. 
2008a). The human 03 mRNA encompasses 2066 nucleotides and contains 220 base 
pairs (bp) of 5' -untranslated region (UTR), an 834 bp open reading frame, and a 3 '-UTR 
of 1012 bp. The amino acid sequence predicts a protein of278 residues with a molecular 
mass of about 32 kDa (Salvatore eta/. 1995). D3 is a selenoprotein, containing a 
selenocysteine-encoding TGA codon and a SEC IS element in the 3 'UTR. The 
selenocysteine residue is contained in the catalytic pocket and is crucial for maximal 
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catalytic efficiency (Kuiper et a!. 2003). The D3 gene is located on human chromosome 
14q32 and is comprised of a single ex on which, in certain tissues, appears to be 
paternally imprinted (Thyroid Disease Manager). 
Regulation of D3 has been observed in both in vitro and in vivo studies (Table 1 ). 
THs have been shown to positively regulate D3 levels at the transcriptional level in 
several systems, which correlates to its important role in maintaining homeostasis when 
TH levels are above or below the normal physiological range (StGermain et a!. 1994, 
Van der Geyten eta!. 1999b ). Other stimulators of 03 in various cell types include 
retinoic acid, various growth factors, and hormones involved in regulating cell 
proliferation (Esfandiari eta!. 1994, Hernandez & Obregon 1995, Wasco eta!. 2003, 
Huang eta!. 2005). Semm and phorbol esters also induce D3 expression in astrocytes and 
preadipocytes (Courtin et a!. 1991 ). 
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Table 1: Transcription Factors and Agents Regulating D3 Expression. D3 
expression is regulated in vivo and in vitro. Table adapted from Dentice 2011 . 
Agent 
Hyperthyroidism 
Retinoic acid 
Se m growth factors 
.se m and phorbol esters 
Estrogens and progesterone 
Glucocorticoids and GH 
TGF~ 
HIF·1 
Shn/Gii2 
EtTects on 03 expression 
t 
i 
t 
i 
i 
L 
t 
t 
t 
7 
.. 
Tili5ue or animal model 
Xenupusleilvis 
Astroglial cells 
Raf brown adipoq1es 
Astroqtes and preadipoc.ytes 
Ovary and deve loping testis 
Chicken embryos 
Fibroblasts, m}·ublasts, and 
hemangioma cells 
Rat heart 
Mouse keratinoq1es and BCC 
Role of D3 in Disease 
A number of pathophysiological conditions associated with severe disease are 
characterized by significant changes in levels of circulating THs and modifications of 
deiodinase pathways. While D3 activity is found in only a limited amount of postnatal 
tissues, its re-expression has been studied in various pathophysiological conditions such 
as cancer, cardiac hypertrophy, myocardial infarction (MI), chronic inflammation, and 
critical illness leading to a reduction ofTHs (Gereben eta!. 2008b). Both systemic and 
local reduction in levels ofTHs may reflect an induction of D3 and/or down-regulation of 
Dl and D2. It is stil l unclear whether the decrease in THs that occurs is an adaptive or 
maladaptive process in many diseases. 
Systemic vs. Local Thyroid Hormone Status 
Changes in deiodinase pathways contribute to both the systemic and local 
bioavailability ofTHs that occur in disease. Both systemic and local changes in THs are 
implicated in non-thyroidal illness syndrome (NTIS), which is characterized by a 
decrease in circulating free T3 and an increase in total rT3 where the degree ofT3 
reduction in sick patients is correlated with prognosis and survival. Recent studies show 
that 03 activity is upregulated locally in liver and skeletal muscle of patients with NTIS, 
which may contribute to systemic decrease in T3 (Peeters eta!. 2003, Boelen eta!. 2005). 
The highest levels of D3 were detected in an infantile human hemangioma, causing 
systemic decrease in THs or 'consumptive hypothyroidism' due to excessive inactivation 
ofT4 and T3 (Huang eta/. 2000). 
8 
Local increase ofD3 mRNA and enzyme activity has also been observed in 
several models of disease including a rat model of heart failure induced by right 
ventricular hypertrophy. In this model, hypoxia led to an increase in hypoxia-inducible 
factor 1 (HIF-1) levels, which was found specifically in the hypertrophic myocardium of 
the right ventricle. HIF-1, which is known to upregulate D3 expression, subsequently 
caused an anatomically specific reduction in local T3 content and action (Simonides et al. 
2008). 
D3 in Infection and Inflammation 
Local alterations in THs and deiodinase pathways are also observed in disease 
models such as infection and inflammation. D3 has been detected in neutrophils that 
infiltrate infected organs in a mouse model of acute bacterial infection (Kwakkel et al. 
201 0). It is thought that D3 increases T3 inactivation and increases levels of iodide (r), 
which is required by myeloperoxidase to allow neutrophils to undertake bacterial 
phagocytosis (Boelen 2009). D3 has also been induced in human cell lines stimulated by 
interleukin-6 (IL-6), which is a cytokine that is a hallmark of the acute phase ofNTIS 
that occurs in chronically ill patients (Wajner 2011). 
Studies in mice have also suggested that D3 is upregulated in infiltrating 
granulocytes in response to chemical and bacterial peripheral inflammation (Boelen et al. 
2005, 2008). Chronic local inflammation was induced by injecting turpentine into the 
hindlimb -which signals activation of specific cytokines - and resulted in a local 
9 
increase of03 in muscle surrounding the abscess while 01 and 03 activities in liver 
remained unchanged (Boelen et a!. 2005). 
D3 in Regeneration 
Studies in partial hepatectomy in rats have also implicated 03 in liver 
regeneration as 'stem-like' cells re-enter the cell cycle. 20 hours after partial 
hepatectomy, 03 activity increased tenfold, 03 mRNA expression increased threefold 
which was associated with a two- to three-fold decrease of liver and semm T3 and T4 
levels (Tanimizu & Miyajima 2007). Concordant results were found in a similar study in 
mice, while no notable difference in 01 or 02 protein or mRNA levels were observed 
(Kester et a!. 2009). These findings display a relationship between TH levels and 
deiodinase pathways during the early phases of regeneration, where increased 03 
expression and resulting decreased TH levels may be necessary for increased cellular 
proliferation. 
D3 in Cancer 
Given that 03 induction is involved in cellular proliferation and THs are 
important for differentiation, it is not surprising that the inactivating enzyme has also 
been detected in malignant cell lines (Kester et al. 2006) and various human tumors 
(Gereben et a!. 2008b ). The Hedgehog cascade (Shh), which is responsible for 
proliferation in various cellular systems, has also been found to upregulate 03 activity via 
a conserved Gli2 binding site on the human Dio3 promoter (Dentice eta!. 2007). This 
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decrease of THs may have effects on apoptosis and tumor progression, although it has not 
been determined if an increase in D3 expression is secondary to tumor formation or if it 
confers selective advantage for growing cancer cells as T3 is a differentiation agent. 
The Role of Blood 
Blood circulates through the body to provide oxygen and essential nutrients (e.g. 
glucose, amino acids, hormones, lipids, antibodies, etc.) to the cells of the body while 
transporting waste products (e.g. carbon dioxide, ammonia, urea, etc.) to the lungs for 
expulsion and to the kidneys for excretion. Blood also serves to distribute body heat 
generated by metabolizing cells through the body to maintain homeostasis and forms 
clots via platelet aggregation and plasma coagulation in the event of vascular injury. 
Whole blood is comprised of plasma and three different cell types: red blood cells 
(erythrocytes, RBC), white blood cells (leukocytes, WBC) and platelets (thrombocytes, 
PLT) (Figure 3). 
II 
Whole Blood 
4- 61iters 
'
-{Water90% Solutes 1 O"k 
Plasma Proteins 7% 
53 - 60% Electrolytes ) 
Urea 34/ Glucose .,. 
Etc. 
{ 
Err~r~:Smmiontmm3 
Formed Elements leukocytes - -----l 
40- 41"/o 6 -10 thousal'ldlmm3 
Platelets 
150 - 400 thousandlmm3 
Albumin 55% 
3.2 - 4.5 gfdl 
Globulins 
(alpha, beta. gamma) .,.1,.. 
2.3- 3.5 g/dl 
Fibrinogen 4% 
0.3 - 0.4 g/dl 
Neutrophils 60 - 70% 
Eoslnophils 2- 4% 
Basophils 0.15% 
Lymphocytes 20 - 25% 
Monocytes 3 - 8% 
Figure 3: The composition of blood. Blood is comprised of three different types 
of cells and many factors that are important in physiological processes and provide 
nutrients to cells. Figure adapted from Schaum' s Easy Outline ofHuman Anatomy and 
Physiology, New York: McGraw-Hill2010. 
All three types of blood cells are derived from hematopoietic stem cells in the 
bone marrow. The progenitor cells undergo cell division and differentiate into competent 
cells that circulate through the blood and lymph vascular system to become available to 
peripheral tissues (Figure 4). Erythrocytes are biconcave sacs composed of 30% 
hemoglobin and other enzymes and small molecules. The hemoglobin carries oxygen and 
allows the red blood cell to perfonn its main task: to transport oxygen and carbon 
dioxide. Leukocytes are the main cells ofthe immune system and participate in immune 
defense. These white blood cells can further differentiate into various cells such as 
monocytes/macrophages and neutrophils which play a role in phagocytosis (ingestion and 
degradation of microbial particles). Lymphocytes include B-cells which synthesize 
antibodies and T-cells which play a role in cellular immunity. Lastly, thrombocytes 
develop from larger megakaryocytes and play a role in blood clotting and inflammation. 
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Figure 4: Hematopoietic cell pathways. All blood cells are derived from stem 
cells in the bone marrow. Taken from immunesytemimmunity.blogspot.com, 2009. 
Thyroid Hormone in the Hematopoietic System 
As stated above, thyroid hormone regulation has been observed in blood cells 
such as granulocytes during inflammation and infection. Thus, one of the many roles of 
THs and deiodinases may be in the regulation of hematopoiesis. Diseases characterized 
by thyroid hormone derangement have also been linked to blood cell abnormalities; 
Graves' disease has been associated with anemia, hyperthyroidism has been associated 
with erythrocytosis, and a decreased red blood count has been observed in patients who 
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have undergone thyroidectomy (Kawa 201 0). Hypothyroidism is also associated with 
anemia or hyperproliferation of immature erythroid progenitors (Kawa 201 0). 
Hyperthyroidism increases the metabolic rate and oxygen consumption of cells, and the 
above-normal production ofTHs induces erythropoietin (EPO) production, which 
stimulates the bone marrow to produce oxygen-containing RBCs. THs have been shown 
to induce EPO gene expression in both normoxic and hypoxic cells via HIF-1 
accumulation (Ma 2004). 
TH effects on leukocytes are varied. Hyperthyroid patients have been observed 
with elevated, normal, or slightly depressed total leukocyte counts (Kawa 201 0). T3 has 
been shown to play an important role in normal lymphocyte production in the bone 
marrow through its regulation ofpro-B cell proliferation (Foster 1999, Arpin 2000). T-
lyrnphocytes cultured with T3 and T4 have also shown enhanced apoptosis while 
lymphocytes in patients with Graves' disease also showed enhanced apoptosis, although 
inhibition of apoptosis has been implicated in autoimmune diseases (Mihara 1999). 
As evidenced, the data on the correlation ofTH levels and pathophysiological 
conditions involving the hematopoietic system are complex and highly varied. 
Abnonnalities in hematological parameters have been noted in patients with deranged 
thyroid status but the exact mechanism ofTH action on hematopoiesis is not clear. TH 
derangements may be caused by autoimmune diseases (as seen in Graves ' disease and 
Hashimoto's thyroiditis), which make it difficult to deduce the exact causes of altered 
blood cell production because of other affected physiological processes that are 
associated with those diseases. This study aims to observe the direct effects of blood-cell-
14 
specific D3 deficiency on hematopoiesis and serum TH levels in a mouse model by 
knocking out the D3 gene specifically in hematopoietic cells and stressing the mouse 
under different conditions. It also aims to study deiodinase induction in human blood cell 
lines in vitro. 
SPECIFIC AIMS AND OBJECTIVES 
Thyroid hormone-inactivating enzyme D3 has been observed in mouse leukocytes 
and mouse bone marrow. The objective of the present study is to determine how D3 may 
regulate blood cell production. We hypothesize that D3 expression in hematopoietic cells 
regulates local thyroid hormone signaling and that its knockdown would increase thyroid 
hormone action. We speculate that this in tum could alter blood cell production in both 
the well state (normal blood cell homeostasis) and in various disease states 
(inflammation, infection, anemia). 
Specifically, 
l . Human and mouse blood cells will be tested in vitro for deiodinase activity in the 
well state and in various disease states. 
2. The complete blood counts of mice with blood-cell-specific D3 deficiency will be 
studied in the well state and in various disease states. 
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3. Thyroid function tests will be conducted on mice with blood-cell-specific D3 
deficiency in the well state and in various disease states. 
These studies should demonstrate a correlation, if any, between pathological 
states and D3 induction in blood cells. They should also shed light on the relationship 
between blood-cell-specific D3, blood cell production, and serum T4 and T3 levels. 
METHODS 
Cell Culture and in vitro Stimulation 
The human T lymphocyte cell line, Jurkat (taken from the peripheral blood of a 
14-year old boy with acute T cell leukemia), and human B lymphocyte cell line, Raji 
(derived from a patient with Burkitt's lymphoma), were grown in RPMI supplemented 
with 10% fetal bovine serum, and 10 I-ll penicillin-streptomycin-glutamine (100%) in an 
incubator kept at 37 oc and 5% carbon dioxide. Cells were maintained at 30% -80% 
confluence in 1 OOmm tissue culture plates. They were fed fresh media when under 80% 
confluence, and passaged when above 80% confluence. 
Deiodinase activity was measured by calculating deiodination in a system using 
radiolabe1ed iodide (1251) and high-performance liquid chromatography. For deiodination 
experiments, 1 x 106 cells were incubated in 1 mL media containing 1 xI 06 cpm 
radiolabeled [3 ',5'- 1251] T3 (PerkinEimer) and selenium (to reach a final concentration of 
10-7 M). Cells were then treated with phorbol 12-myristate 13-acetate (TPA) (Sigma-
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Aldrich), which is a potent tumor promoter that stimulates interleukin production, in a 
vehicle of 100% ethanol to reach a final concentration of 1o-7 M. The same cells were 
also treated with ionomycin, which is an ionophore that stimulates cytokines and 
interleukins, in a vehicle of dimethyl sulfoxide (DMSO) to reach a final concentration of 
0.5 )lM. Drug treated cells were compared to cells treated with vehicle (I 00% ethanol 
and DMSO) and wells that contained no cells (to control for nonspecific deiodination). 
Cells were harvested along with media after 24 hours and placed into a -80 oc freezer 
overnight to allow the cell membranes to lyse, then processed by HPLC the following 
day. 
Deiodinase Activity Assays 
Deiodination assays were conducted by HPLC. After lysing the cell membrane in 
-80 oc overnight, 150 )ll of cells were placed into a 2.0 mL tube (Eppendorf) to which an 
equal amount of 100% ice-cold methanol was added. The tubes were vortexed for 4 
minutes to stop additional deiodination, then centrifuged at 13,800 revolutions per minute 
for 5 minutes. 275 )ll of supernatant were placed into 1 mL glass HPLC vials (Fisher 
Scientific) and 325 ~d of a mixture of 0.02 M ammonium acetate pH 4, methanol, and 
O. lM potassium phosphate buffer ph 6.9 with lmM EDTA were added and vortexed 
briefly. Vials were then analyzed by HPLC, which detected amounts (in counts per 
million) of radio labeled substrate and products. 
Deiodinase activity was measured by analyzing the fractional conversion of 
substrates into products. D 1 fractional conversion measured the conversion of rT3 by 
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dividing the amount of products (T2 +free r) by the total amount of substrate and 
products (rT3 + T2 + r). D2 fractional conversion measured the conversion ofT4 into T3 
or free iodide. D3 fractional conversion measured the conversion ofT3 into T2 and Tl. 
Quantitative amounts of radiolabeled substrates and products were measured by high-
performance liquid chromatography (Waters 1525 Binary HPLC pump and Packard 
500TR Series Flow Scintillation Analyzer). Each product was eluted at different times, 
which was inversely related to mass (i.e. T3 eluted later than T2, and T2 later than Tl). 
Anima/Care 
Mice were kept in 12-hr light, 12-hr dark cycles in a temperature-controlled room 
and received food and water ad libitum. Mice were weaned at 3 weeks of age and 
separated by sex. 
Complete Blood Count 
Male and female 03 Flox/Flox, Vav-iCre +/-and D3 Flox/Flox, Vav-iCre -/-
mice were studied at 4 weeks of age. Blood was collected by cardiac puncture using a 25-
gauge needle, and 250 f .. d were immediately placed in EDT A-treated lavender-top tubes 
(Becton, Dickinson and Company, Franklin Lakes, NJ) to prevent clotting. Samples were 
stored on ice until analysis and were analyzed within 8 hours of collection. Complete 
blood counts (CBCs) were measured using the VetScan HM2 Hematology System 
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(Abaxis, Union City, CA) according to HM2 CBC protocol. All data were processed 
using Microsoft Excel. 
Thyroid Function Tests 
Serum T4 and T3 were measured using the Total T4 and Total T3 Coat-a-Count 
RIA kits (SIEMENS) according to the manufacturer's protocol except for the following 
amendments: 6.25 j..LI of serum were used for T4 measurements with 250 j..LI of 125! Total 
T4 provided in the kit, and incubated in a 37 oc water bath for two hours; 25 j..LI of serum 
were used for T3 measurements with 250 j..LI of 1251 Total T3 provided in the kit, and 
incubated in a 37 oc water bath for 4 hours. Tubes were counted for 5 minutes using a 
tr protocol for )I on a Gamma counter. 
DNA Extraction from Blood 
DNA was prepared from blood cells by a method provided by The Jackson 
Laboratory in which 100 j..Ll of whole blood collected from cardiac puncture were 
immediately placed into a tube containing 20 j..LI of 10 mM EDTA and gently mixed by 
pipetting up and down. All samples were stored on ice until processing. After mixing 
with EDTA, 200 j..LI of a lysis mixture containing 0.32 M Sucrose, 1 OmM Tris-HCl (pH 
7.5), 5 mM MgCh andl % v/v Triton X-100 were added and vortexed briefly. Tubes were 
then centrifuged at 13,800 revolutions per minute to pellet nuclei. The supernatant was 
discarded and another 200 j..Ll of the lysis mixture were added, repeating the above steps 
of vortexing, centrifuging, and decanting supernatant. This lysis step was repeated a third 
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time. 
The nuclear pellet was then resuspended in I 00 111 of sterilized buffer containing 
50 mM KCl, 10 mM Tris-HCl (pH 8.3), 2.5 mM MgCh, 0.1 mg/m1 gelatin, 0.45% (v/v) 
Nonidet P40, and 0.45% (v/v) Tween 20 to which 60 llg/ml proteinase K was added 
immediately prior to use. This was then incubated at 55 oc for 60 minutes then at 95 oc 
for 10 minutes (to inactivate the proteinase K) . 1-5 111 of this extracted DNA was then 
used in polymerase chain reaction (PCR). 
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RESULTS 
Deiodinase Activity Assays in Human Blood Cell Lines 
03 mRNA and activity are detectable in blood cells isolated directly from WT 
mice (data not shown). In order to develop a more convenient in vitro model of blood cell 
deiodination, a number of commonly used and well-established blood celllines- Jurkat 
cells (T lymphocytes derived from the blood of a 14-year old boy with acute T cell 
leukemia) and Raji cells (B lymphocytes derived from a patient with Burkitt ' s 
lymphoma}- were screened. T- and B-lymphocytes were treated with a potent tumor 
promoter (TPA) and an ionophore (ionomycin) and incubated for 24 hours. 
01 activity was measured by calculating the fractional conversion of substrate 
rT3 into the products T2 and free r. 02 activity was measured by calculating the 
fractional conversion of substrate T4 into the products T3 and free r. 03 activity was 
measured by calculating the fractional conversion of substrate T3 into the products T2 
and Tl. No statistically significant deiodinase activity (i .e. above background) was 
measured in either Jurkat or Raj i cells as shown in Figures 5 and Sa (0 I and 02 activity 
not shown). 
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03 activity in Jurkat cells 
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Figure 5: D3 enzyme activity in Jurkat cells. D3 induction was not statistically 
significant above background. 
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Figure Sa: D3 enzyme activity in Raji cells. D3 induction was not statistically 
significant above background. 
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Based upon the above results the blood cells tested do not expresses significant 
deiodinase activity under the experimental conditions used. Based upon our positive 
results ofD3 activity in blood cells from WT mice, we will continue to explore 
conditions which permit deiodinase expression in cultured blood cells. If necessary, we 
will develop conditions to maintain primary blood cells from mice in vitro. 
Creation of a Conditional D3 Knockout Mouse with Blood-Cell-Specific D3 Deficiency 
Based upon our early studies demonstrating the specific expression ofD3 mRNA 
and activity in mouse leukocytes, we designed a strategy to knockdown D3 expression 
specifically in blood cells. This was accomplished using the Cre-lox system, which was 
developed in the 1990s and allows for conditional gene knockouts and reporter 
expression. The mechanism was discovered in Pl bacteriophage as part of the organism's 
normal viral life cycle in which it uses the Cre-lox system to circularize and facilitate 
replication of its genomic DNA (Sauer and Henderson 1988, Sternberg and Hamilton 
1981 ). LoxP sites are defined by a specific 34-base pair sequence containing an 8-bp core 
sequence, and two flanking inverted repeats (Figure 6). 
ATAACTTCGTATAGCATACATTATACGAAGTTAT 
Figure 6: The 34-base pair loxP sequence. The core sequence (underlined) is 
surrounded by two inverted repeats. Figure adapted from The Jackson Laboratory. 
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Cre recombinase is an enzyme that catalyzes recombination between two loxP 
sites. Depending on the orientation and location of the loxP sites, the recombination can 
cause a deletion, inversion, or translocation of a gene (Figure 7). In the case of the D3 
Flox mouse (developed in the laboratory of Dr. P. Reed Larsen, Brigham and Women's 
Hospital), a critical sequence of the 3' untranslated region of the D3 gene is flanked by 
two loxP sites that are oriented in the same direction. In the presence of Cre recombinase, 
the loxP flanked (floxed) target is excised and results in a tnmcated, enzymatically-
inactive D3 protein. 
A 
Inversion 
8 
T ronslocofion 
c 
Deletion 
Figure 7: Cre recombinase mechanism. The orientation and location of loxP 
sites determine the result of recombination. If the loxP sites are in the same direction on a 
chromosome segment, recombination will cause a deletion (C). Figure adapted from The 
Jackson Laboratory. 
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The mouse model of blood-cell-specific D3 deficiency was developed by crossing 
homozygous D3 Flox mice with a commercially available blood-cell-specific Cre driver 
line, the Vav-iCre transgenic mouse (Strain B6.Cg-Tg (Vavl-cre) A2Kio/J) from the 
Jackson Laboratory (Bar Harbor, Maine). The offspring of this cross (Cross 1) that had a 
genotype ofD3 Flox/WT, Vav-iCre +/-were then crossed with a D3 Flox/Flox mouse to 
create Cross 2. Any offspring of Cross 2 that had a genotype ofD3 Flox/Flox were 
studied. Mice that were hemizygous for the Cre transgene were assumed to have blood-
cell-specific D3 deficiency and were compared to D3-sufficient Cre-negative littermates. 
For simplicity, mice with the D3 Flox/Flox, Vav-iCre +/-genotype will be referred to as 
D3KO-blood mice in the remainder of this thesis. 
Preliminary Phenotyping of the D3KO-blood Mouse 
We generated the D3KO-blood mouse as a tool to model the potential role ofD3 
in normal blood cell homeostasis as well as its role in leukocyte function. At the time of 
the submission of this thesis, we have completed some phenotyping ofthe D3KO-blood 
mouse in the well state. 
1) Complete Blood Counts 
Blood was collected from healthy 4-week old D3KO-blood female and male mice 
and complete blood counts were performed on the Abaxis VetScan HM2 platform. Vav-
iCre negative littermates were also analyzed as a negative control. As shown in Tables 2 
and 3 below, no significant difference was seen between these two genotypes, indicating 
25 
that the loss ofD3 in hematopoietic cells alone is not sufficient to cause pancytopenia. If 
confirmed in mice collected at other time points, the baseline of normal blood cell counts 
predicts that any abnormalities we see in future inflammation models can be attributed 
specifically to the expression of D3 in these pathophysiologic states. 
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Table 2: Complete blood counts in 4-week old female mice. Baseline values 
were not statistically significant between female mice with functional hematopoietic D3 
and mice that did not have functional hematopoietic D3. 
Vav-iCre -/-average Vav-iCre +/-average 
(n=S) (n=S) p-value 
Parameter 
WBC (109 cells/1) 8.050 ± 3.96 7.340 ± 2.08 0.73 
L YM (1 09 cells/1) 7.622 ± 3.68 6.748 ± 1.83 0.65 
MON (1 0':1 cells/1) 0.222 ± 0.16 0.252 ± 0.22 0.81 
GRA (1 09 cells/1) 0.206 ± 0.22 0.340 ± 0.14 0.29 
RBC (1 0 12 cells/1) 8.656 ± 1.03 9.172±0.72 0.39 
HGB (g/dl) 14.040 ± 1.77 15.160 ± 1.19 0.28 
HCT% 0.403 ± 0.05 15.045 ± 19.60 0.37 
MCV (fl) 46.600 ± 1.14 47.000 ± 2.55 0.76 
MCH (pg) 16.180±0.61 16.560 ± 0.67 0.38 
MCHC (g/dl) 34.820 ± 0.94 35.220 ± 0.72 0.47 
RDWc% 0.182 ± 0.01 6.722 ± 8.77 0.37 
PLT (109/l) 384.200 ± 311.26 440.200 ± 214.99 0.75 
PCT% 0.003 ± 0.00 0.155 ± 0.20 0.37 
MPV (fl) 7.000 ± 0.47 6.940 ± 0.38 0.83 
PDWc% 0.311 ± 0.03 10.069 ± 13.10 0.37 
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Table 3: Complete blood counts in 4-week old male mice. Baseline values were 
not statistically significant between male mice with functional hematopoietic D3 and 
mice that did not have functional hematopoietic D3. 
Vav-iCre -/-average Vav-iCre +/-average 
(n=7} (n=6) p-value 
Parameter 
WBC (1 a~ cells/!) 6.546 ± 1.88 7.065 ± 1.69 0.61 
L YM ( 1 a \I cells/1) 5.778 ± 1.72 6.455 ± 1.51 0.48 
MON (1 a~ cells/1) 0.367 ± 0.34 0.278 ± 0.23 0.59 
GRA ( 1 a \I cells/1) 0.204 ± 0.24 0.335 ± 0.39 0.49 
RBC {la 1:l cells/!) 8.437 ± 0.76 8.497 ± 0.84 0.90 
HGB (g/dl) 13.357 ± 2.02 14.017±1.34 0.50 
HCT% 0.403 ± 0.04 13.363 ± 20.30 0.18 
MCV (fl) 4 7.857 ± 1.68 47.500 ± 1.22 0.67 
MCH (pg) 15.800 ± 1.58 16.500 ± 0.51 0.30 
MCHC (g/dl) 33.086 ± 2.99 34.683 ± 0.48 0.21 
RDWc% 0.185 ± 0.01 6.232 ± 9.36 0.17 
PLT (la~/1) 505.429 ± 276.82 538.833 ± 405.82 0.87 
PCT % 0.004 ± 0.00 0.073 ± 0.13 0.24 
MPV (fl) 6.957 ± 0.16 7.733 ± 1.72 0.32 
PDWc% 0.307 ± 0.02 10.826 ± 16.38 0.18 
2) Serum Thyroid Hormone Levels 
Next, we performed serum thyroid function tests on 03KO-blood mice and Vav-
iCre negative littermates. Serum T4 and serum T3 concentrations were similar between 
both genotypes in females (Figures 8 and 9) and males (Figures 8a and 9a). This indicates 
that the 03 expression we have documented in blood cells ofWT mice is not necessary 
for the maintenance of systemic euthyroidism in the well state. Based upon the work of 
other researchers who have raised the hypothesis that 03 induction in blood cells during 
severe illness is a contributor to the hypotriiodothyronemia of the non-thyroidal illness 
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syndrome, we will test this hypothesis directly though future experimentation using this 
genetic mouse model. As detailed in the background section, the normal serum thyroid 
hormone concentrations in the D3KO-blood mouse do not negate the possibility that 
blood cell D3 is an important intracellular regulator oflocal thyroid status as Dl and/or 
D2 may play a role in compensation. 
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Figure 8: Serum T4levels in 4-week old female mice. Serum T4levels were not 
statistically significant between female mice with functional hematopoietic D3 and mice 
that did not have functional hematopoietic D3 . 
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Figure Sa: Serum T4levels in 4-week old male mice. Serum T4levels were not 
statistically significant between male mice with functional hematopoietic D3 and mice 
that did not have functional hematopoietic D3. 
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Figure 9: Serum T3 levels in 4-week old female mice. Serum T3 levels were not 
statistically significant between male mice with functional hematopoietic D3 and mice 
that did not have functional hematopoietic D3 . 
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Figure 9a: Serum T3levels in 4-week old male mice. Serum T3 levels were not 
statistically significant between male mice with functional hematopoietic 03 and mice 
that did not have functional hematopoietic 03 . 
Genotyping of the D3KO-blood Mouse 
Genotyping ofD3 Flox/Flox, Vav-iCre+/- or 03 Flox/Flox, Vav-iCre-/- mice was 
conducted by polymerase chain reaction using DNA from whole blood and primers that 
anneal outside of the two loxP sites in the 03 gene 3' UTR. Blood-cell-specific 
recombination occurred in the presence of the trans gene, cutting out the 3' UTR of the 
03 gene and one loxP site (Figure 1 0). Genotyping of the blood of a mouse with the 
trans gene therefore resulted in a smaller molecular weight product (786 bp) while 
genotyping of a mouse without the trans gene resulted in a larger molecular weight 
product ( 1484 bp) as seen in Figure 1 Oa. 
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3'UTR 
1484 bp 
Cre recombinase 
.. 
786 bp 
Figure 10: Cre-lox recombination of the flo xed D3 allele. The presence of Cre 
recombinase causes the deletion of the D3 allele 3 'UTR and one loxP site, leaving a 
truncated and enzymatically-inactive D3 . The red arrows represent the location ofPCR 
primer annealing while the green lines represent the resultant PCR amplicon. 
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Due to time, only a limited number of pilot PCR experiments on this genomic 
DNA were possible before the submission of this thesis. These data were encouraging in 
that the low molecular weight PCR amplicon corresponding to recombination of the D3 
allele was observed in three mice that were hemizygous for the Vav-iCre transgene 
(Figure lOa: lanes 1-3). 
In contrast, DNA prepared from one mouse that was negative for the Cre 
transgene showed only the high molecular weight amplicon corresponding to the 
unrecombined flo xed D3 allele (Figure 1 Oa: lane 4 ). Of note, the PCR reaction shown in 
Figure lOa is not yet reproducible and occasionally shows inconsistent results with 
amplification of the low molecular weight (recombined) amplicon in DNA obtained from 
other Cre negative mice. Thus, a future goal is to troubleshoot and optimize techniques 
and focus efforts to eliminate PCR contamination. If unable to achieve consistent PCR 
results, Southern blotting experiments will be considered to demonstrate specific 
recombination at the level of DNA. Western blotting or enzyme assays will also be 
considered to demonstrate knockdown of D3 protein. 
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1484 bp 
786 bp 
Figure lOa: Genotype to show recombination in blood ofD3 Flox/Fiox mice 
with the Vav-iCre transgene. PCR ofD3 Flox/Flox mice with the blood-specific 
transgene resulted in a truncated amplicon of786 bp (lanes 1-3) while lack ofthe 
transgene resulted in a full-length amplicon of 1484 bp (lane 4). 
DISCUSSION 
It is well accepted that thyroid hormone is a critical regulator of cellular 
proliferation and differentiation and that deiodination is the main pathway of thyroid 
hormone metabolism in mammals. Based upon recent studies which show high 03 
expression in progenitor cells as well as in differentiated cells undergoing rapid 
proliferation, we became interested in studying the hematopoietic system as a classic 
model of both these phenomena. In preliminary data (not shown) our group documented 
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D3 mRNA and enzyme activity in blood cells from WT mice. Accordingly, this thesis 
project was to screen in vitro blood cell models and to develop an animal model to study 
hematopoietic 03 expression through conditional Cre-lox mediated knockdown. 
To develop a tissue culture model of blood cell deiodination, two well-
characterized human celllines- Jurkat cells (T lymphocytes derived from the blood of a 
14-year old boy with acute T cell leukemia) and Raji cells (B lymphocytes derived from a 
patient with Burkitt' s lymphoma)- were screened. Thus far, these cell types show no 
significant deiodinase activity under our screening conditions. This may indicate that the 
03 expression we have observed in normal blood cells (data not shown) may be lost in 
blood cell cancers. Alternatively, it may be that 03 expression can be induced in these 
cell lines by modification of tissue culture conditions or exposure to cytokines. Our 
experience with 03 expression in other cell types creates optimism that the latter is true, 
so a future direction of this project is to continue testing stimulators and to screen other 
established cell lines . If necessary, the possibility of studying blood cell de iodination in 
primary cell cultures will also be explored. 
The second goal of this project was to develop a mouse model of blood-cell-
specific 03 deficiency. Through the course of this project, mouse husbandry and 
breeding strategies as well as the application of the Cre-lox system to create conditional 
gene knockout animals were employed. Due to timing, characterization of the D3KO-
blood mouse has only just started. Preliminary data support that the floxed 03 allele is 
recombined in the blood cells of Vav-iCre+/- mice (Figure I Oa). Further work will be 
necessary to confirm this result with additional PCR experiments and Southern blotting. 
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Pending these results, the efficiency of D3 knockdown at the level of protein by Western 
blot and enzyme activity assay will be determined. Based upon other conditional D3 
knockout animals generated in Dr. Huang's laboratory, we predict that recombination of 
the floxed allele will result in near-complete knockdown ofD3 activity in blood cells. 
Our preliminary phenotyping of the D3KO-blood mouse indicate that its complete 
blood counts and systemic thyroid status are normal (Tables 2 and 3, Figures 8, 8a, 9 and 
9a). This supports that D3 deficiency alone is not sufficient to alter normal blood cell 
homeostasis or serum thyroid hormone concentrations. Based upon experience with 
previously published deiodinase knockout mice, it is possible that D3 plays an important 
role in both these processes but that compensation of the other deiodinases (D 1 and D2) 
explains the apparently normal phenotype we have observed thus far in the well state. 
Pending the confirmatory studies outlined above, it is promising that the D3 
knockout-blood mouse can serve as an excellent model to study the role of deiodination 
in inflammation, infection, and anemia on blood cell production, differentiation, and/or 
function. 
CONCLUSION 
In summary, we developed a new mouse model in which the thyroid hormone 
inactivating enzyme was knocked out of the hematopoietic system. We proved that 
recombination using Cre-lox technology was successful in knocking out 03 in blood cell 
through PCR of DNA extracted from blood. We found that blood-cell-specific D3 
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deficiency was not sufficient to induce pancytopenia or deranged TH status in healthy 
mice. Our results provide a useful tool for future studies in the role ofD3 in disease. 
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